Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG001419 Phase 1 SAD/MAD and Food Effect Study in Healthy Subjects
NCT06636500Phase 1Completed
- Sponsor
- Cullgen Inc.
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pain comparing CG001419 Arm with Placebo Arm (2 arms). Primary endpoint: Safety and Tolerability of CG001419 at 7 days. Started Jan 2025; status: completed.
02
Drugs
CG001419
03
Conditions
pain
Beyond the preview
Go deeper on NCT06636500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06636500.